WEDNESDAY, March 5, 2025 -- For patients with psoriasis, Amjevita and Imraldi are as effective as Humira for new users and in a switcher analysis, according to a study published online March 5 in JAMA Dermatology.

Duc Binh Phan, from the University of Manchester in the United Kingdom, and colleagues compared the effectiveness of adalimumab biosimilars Amjevita and Imraldi to Humira for psoriasis in an emulation of two targeted pragmatic clinical trials. A total of 11,400 patients were included. The new user analysis included 6,133 patients (5,416 starting Humira; 382 starting Amjevita; 335 starting Imraldi), and 5,267 patients were included in the switcher analysis (3,808 continuing Humira; 847 switching to Amjevita; 612 switching to Imraldi).

The researchers found that compared with Humira users, Amjevita and Imraldi new users exhibited no significantly different probability of achieving a Psoriasis Area and Severity Index (PASI) score of 2 or less or a PASI score of 4 or less. No significant differences in achieving a PASI score of 2 or less or a PASI score of 4 or less were seen for patients who switched to Amjevita and Imraldi versus those who continued Humira.

"In this study, Amjevita and Imraldi were as effective as the originator Humira for the treatment of psoriasis," the authors write.

Several authors disclosed ties to the pharmaceutical industry.